J Clin Oncol 2022 Mar 20
Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.
Related Questions
How would you approach the treatment if the tumor is PDL1+?
New answer by at University of Kentucky College of Medicine (January 5, 2023)
Recurrent ovarian carcinosarcoma (OCS) is a difficult clinical scenario with few evidence-based options. Clearly, a need exists for novel therapies, and a frank discussion on ...